Home › Resources › Redefining Pancreatic Ductal Adenocarcinoma Survival: Precision Medicine Is Breaking KRAS Barrier
White Paper
November 5, 2026
Redefining Pancreatic Ductal Adenocarcinoma Survival: Precision Medicine Is Breaking KRAS Barrier
Read or save the full PDF
Current drug development for PDAC is now breaking through the “undruggable” barrier, opening a path toward targeted, combination-based precision medicine that could meaningfully change patient outcomes. In this white paper, we’ll look at the evolution of PDAC therapies, the burden of pancreatic cancer, the clinical trial landscape and importance of combination therapies, and the new era in treatment.
PDAC is the most prevalent form of pancreatic cancer and one of the deadliest.
What does it mean that PDAC has been considered “undruggable”?
The KRAS barrier has long limited targeted drug development in PDAC. Current drug development is now breaking through that barrier. In PDAC, this barrier refers to the historic and biological challenges of targeting the KRAS protein, along with the physical and immune barriers that mutant KRAS builds inside the tumor
Why are RAS inhibitors important in PDAC?
RAS inhibitors are opening a path toward targeted, precision medicine for PDAC that could meaningfully change patient outcomes.
Why do combination therapies matter in PDAC?
Combination therapies are a key part of the clinical trial landscape. The white paper describes a new treatment era built on targeted, combination-based precision medicine.
